Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply
Adds new sourcing in paragraph 1, adds details throughout
Oct 4 (Reuters) -GSK GSK.L, Sanofi SASY.PA and CSL Ltd CSL.AX have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a health official said on Friday during a press briefing.
The move comes as a multi-state outbreak among livestock and poultry has caused human illnesses and infected more than 254 herds in 14 states since March, according to government data.
The companies will use the funds to fill vials and pre-filled syringes so that doses can be ready to distribute if needed, said David Boucher, director of Infectious Disease Preparedness and Response for the U.S. Department of Health and Human Services.
The latest award includes $37.9 million for CSL, $23.4 million for Sanofi and $10.5 million for GSK.
It wouldmore than double the country's supplyof shots targeting bird flu, raising the country's total supply of ready-to-use doses to 10 million within the first quarter of 2025.
GSK, Sanofi and CSL will also make additional bulk vaccine ingredients matched to circulating strains of bird flu, Boucher said.
Australia's CSL recently secured a contract worth $121.4 million to increase the U.S. government's stockpile for bird flu vaccines to 40 million doses.
CSL and GSK did not immediately respond to a Reuters request for comment. Sanofi redirected Reuters to the Biomedical Advanced Research and Development Authority, a part of HHS that issued the reward.
Reporting by Sriparna Roy and Christy Santhosh in Bengaluru and Ahmed Aboulenein in Washington; Editing by Shreya Biswas and Mark Porter
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
